Price T Rowe Associates Inc Celldex Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,880,365 shares of CLDX stock, worth $64.1 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,880,365
Previous 3,172,399
9.21%
Holding current value
$64.1 Million
Previous $117 Million
16.61%
% of portfolio
0.01%
Previous 0.01%
Shares
16 transactions
Others Institutions Holding CLDX
# of Institutions
194Shares Held
64.9MCall Options Held
1.65MPut Options Held
973K-
Wellington Management Group LLP Boston, MA8.98MShares$200 Million0.04% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$104 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$86.4 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$77 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$74.2 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.04B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...